1-cyclopropyl-6-fluoro-7-(4-(3-(4-(N-(5-methylisoxazol-3-yl)sulfamoyl)phenylamino)-3-oxopropyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

ID: ALA5076468

PubChem CID: 166626716

Max Phase: Preclinical

Molecular Formula: C30H31FN6O7S

Molecular Weight: 638.68

Molecule Type: Unknown

Associated Items:

This compound is not in our inventory system

Names and Identifiers

Canonical SMILES:  Cc1cc(NS(=O)(=O)c2ccc(NC(=O)CCN3CCN(c4cc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)cc2)no1

Standard InChI:  InChI=1S/C30H31FN6O7S/c1-18-14-27(33-44-18)34-45(42,43)21-6-2-19(3-7-21)32-28(38)8-9-35-10-12-36(13-11-35)26-16-25-22(15-24(26)31)29(39)23(30(40)41)17-37(25)20-4-5-20/h2-3,6-7,14-17,20H,4-5,8-13H2,1H3,(H,32,38)(H,33,34)(H,40,41)

Standard InChI Key:  DFRHRVRXNJHTIM-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 45 50  0  0  0  0  0  0  0  0999 V2000
   18.9811  -15.1180    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   18.5767  -14.4123    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   18.1677  -15.1154    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   26.3674  -10.7720    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.3663  -11.5916    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.0743  -12.0005    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.0726  -10.3632    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.7812  -10.7684    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.7800  -11.5936    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.4901  -12.0050    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   29.2059  -11.5957    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.2071  -10.7705    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.4925  -10.3546    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.9158  -10.3636    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.6225  -10.7739    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   29.9178   -9.5464    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   28.4878  -12.8221    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.4925   -9.5374    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   28.0809  -13.5288    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.8981  -13.5311    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.6596  -10.3636    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   25.6583  -11.9996    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   24.9546  -11.5860    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.2487  -11.9906    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.2438  -12.8081    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   24.9510  -13.2194    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.6631  -12.8132    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.5342  -13.2134    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.8284  -12.8016    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.1188  -13.2070    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.4130  -12.7951    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   20.7034  -13.2005    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.1151  -14.0242    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   20.0001  -12.7855    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.2910  -13.1902    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.2868  -14.0082    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.9976  -14.4199    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.7038  -14.0129    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.8714  -14.0036    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   17.1631  -14.4111    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.4178  -14.0815    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   15.8701  -14.6880    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   16.2776  -15.3963    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.0771  -15.2276    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.9441  -16.1424    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  2  0
  4  5  2  0
  5  6  1  0
  6  9  2  0
  8  7  2  0
  7  4  1  0
  8  9  1  0
  8 13  1  0
  9 10  1  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 12 14  1  0
 14 15  1  0
 14 16  2  0
 10 17  1  0
 13 18  2  0
 19 17  1  0
 20 19  1  0
 17 20  1  0
  4 21  1  0
  5 22  1  0
 22 23  1  0
 22 27  1  0
 23 24  1  0
 24 25  1  0
 25 26  1  0
 26 27  1  0
 25 28  1  0
 28 29  1  0
 29 30  1  0
 30 31  1  0
 31 32  1  0
 30 33  2  0
 32 34  2  0
 34 35  1  0
 35 36  2  0
 36 37  1  0
 37 38  2  0
 38 32  1  0
 36  2  1  0
  2 39  1  0
 39 40  1  0
 40 41  2  0
 41 42  1  0
 42 43  1  0
 43 44  2  0
 44 40  1  0
 43 45  1  0
M  END

Alternative Forms

  1. Parent:

    ALA5076468

    ---

Associated Targets(non-human)

parC Topoisomerase IV (350 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
gyrB DNA gyrase (2092 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Staphylococcus aureus (210822 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Escherichia coli (133304 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 638.68Molecular Weight (Monoisotopic): 638.1959AlogP: 3.42#Rotatable Bonds: 10
Polar Surface Area: 167.08Molecular Species: ACIDHBA: 10HBD: 3
#RO5 Violations: 1HBA (Lipinski): 13HBD (Lipinski): 3#RO5 Violations (Lipinski): 2
CX Acidic pKa: 5.51CX Basic pKa: 6.73CX LogP: 1.27CX LogD: 0.01
Aromatic Rings: 4Heavy Atoms: 45QED Weighted: 0.23Np Likeness Score: -1.76

References

1. Ibrahim NM, Fahim SH, Hassan M, Farag AE, Georgey HH..  (2022)  Design and synthesis of ciprofloxacin-sulfonamide hybrids to manipulate ciprofloxacin pharmacological qualities: Potency and side effects.,  228  [PMID:34871841] [10.1016/j.ejmech.2021.114021]

Source